Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
July 12, 2021 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Topical roflumilast potential “Best-in-Class” topical PDE4 inhibitorSeborrheic dermatitis affects 10 million patients in the U.S.Potential first new topical treatment for seborrheic dermatitis in...
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
December 03, 2019 08:00 ET
|
Dermavant Sciences, Inc.
Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligoTop-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 ...
PROVECTUS BIOPHARMACEUTICALS PROVIDES DRUG DEVELOPMENT UPDATE FOR IMMUNO-DERMATOLOGY ASSET PH-10
November 14, 2018 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on the Company’s small molecule clinical development program for its investigational...